© 2020 MJH Life Sciences and OncLive. All rights reserved.
February 26, 2013
Linda T. Vahdat, MD, from the Weill Cornell Medical College, discusses the combination of eribulin mesylate and trastuzumab as a first-line therapy for HER2-positive metastatic breast cancer.
January 18, 2012
Dr. Linda Vahdat, from New York-Presbyterian Hospital, Discusses the Side Effects of Halaven
December 22, 2011
Dr. Linda Vahdat, from the New York-Presbyterian Hospital, Compares Halaven and Ixempra Neuropathy